Clinical Trial Update: Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ibrutinib in steroid-refractory autoimmune hemolytic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Eugene Nikitin | Conditions: AIHA - Warm Autoimmune Hemolytic Anemia | Phase 2 | Status: UNKNOWN